MedTrace Logo

Tygacil Drug Use Investigation

NCT01789905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2019-02-06

Study results available
· View outcomes & findings →

Summary

Secondary Data Collection Study; safety and effectiveness of Tigecycline .under Japanese medical practice

Conditions

  • Intra-Abdominal Infections
  • Skin Disease, Infectious

Interventions

DRUG

Tigecycline (Tygacil)

Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-15
Primary Completion
2017-06-16
Completion
2017-06-16

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789905 on ClinicalTrials.gov